Abstract:Type 1 diabetes mellitus (T1DM) arises from the failure of pancreatic β-cells to produce adequate insulin, usually as a consequence of extensive pancreatic β-cell destruction. T1DM is classed as an immune-mediated condition. However, the processes that drive pancreatic β-cell apoptosis remain to be determined, resulting in a failure to prevent ongoing cellular destruction. Alteration in mitochondrial function is clearly the major pathophysiological process underpinning pancreatic β-cell loss in T1DM. As with many medical conditions, there is a growing interest in T1DM as to the role of the gut microbiome, including the interactions of gut bacteria with Candida albicans fungal infection. Gut dysbiosis and gut permeability are intimately associated with raised levels of circulating lipopolysaccharide and suppressed butyrate levels, which can act to dysregulate immune responses and systemic mitochondrial function. This manuscript reviews broad bodies of data on T1DM pathophysiology, highlighting the importance of alterations in the mitochondrial melatonergic pathway of pancreatic β-cells in driving mitochondrial dysfunction. The suppression of mitochondrial melatonin makes pancreatic β-cells susceptible to oxidative stress and dysfunctional mitophagy, partly mediated by the loss of melatonin's induction of PTEN-induced kinase 1 (PINK1), thereby suppressing mitophagy and increasing autoimmune associated major histocompatibility complex (MHC)-1. The immediate precursor to melatonin, N-acetylserotonin (NAS), is a brain-derived neurotrophic factor (BDNF) mimic, via the activation of the BDNF receptor, TrkB. As both the full-length and truncated TrkB play powerful roles in pancreatic β-cell function and survival, NAS is another important aspect of the melatonergic pathway relevant to pancreatic β-cell destruction in T1DM. The incorporation of the mitochondrial melatonergic pathway in T1DM pathophysiology integrates wide bodies of previously disparate data on pancreatic intercellular processes. The suppression of Akkermansia muciniphila, Lactobacillus johnsonii, butyrate, and the shikimate pathway-including by bacteriophages-contributes to not only pancreatic β-cell apoptosis, but also to the bystander activation of CD8+ T cells, which increases their effector function and prevents their deselection in the thymus. The gut microbiome is therefore a significant determinant of the mitochondrial dysfunction driving pancreatic β-cell loss as well as 'autoimmune' effects derived from cytotoxic CD8+ T cells. This has significant future research and treatment implications.

Immune and Pancreatic β Cell Interactions in Type 1 Diabetes

Cross Talk between β Cells and Immune Cells: What We Know, What We Think We Know, and What We Should Learn

Innate Immunity in Type 1 Diabetes

Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?)

Advances in the Cellular Immunological Pathogenesis of Type 1 Diabetes.

Presumption of innocence for beta cells: why are they vulnerable autoimmune targets in type 1 diabetes?

The β-Cell in Type 1 Diabetes Pathogenesis: A Victim of Circumstances or an Instigator of Tragic Events?

Transcriptional Control of Pancreatic Β-Cell Identity and Plasticity During the Pathogenesis of Type 2 Diabetes.

The immunology of type 1 diabetes

Immune perturbations in human pancreas lymphatic tissues prior to and after type 1 diabetes onset

Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive

Decoding the immune dance: Unraveling the interplay between beta cells and type 1 diabetes

Therapeutic Strategies for Diabetes: Immune Modulation in Pancreatic β Cells

Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus

Rebalancing the Immune System to Treat Type 1 Diabetes

Type I Diabetes Pathoetiology and Pathophysiology: Roles of the Gut Microbiome, Pancreatic Cellular Interactions, and the 'Bystander' Activation of Memory CD8+ T Cells

Type 1 diabetes: immune pathology and novel therapeutic approaches

The Extra-Islet Pancreas Supports Autoimmunity in Human Type 1 Diabetes

Targeting of pancreatic glia in type 1 diabetes

Breaking and restoring immune tolerance to pancreatic beta-cells in type 1 diabetes

Revisiting the Antigen-Presenting Function of β Cells in T1D Pathogenesis